Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 4:6:1423790.
doi: 10.3389/fdgth.2024.1423790. eCollection 2024.

Advancements in eye movement measurement technologies for assessing neurodegenerative diseases

Affiliations
Review

Advancements in eye movement measurement technologies for assessing neurodegenerative diseases

Tali G Band et al. Front Digit Health. .

Abstract

Eye movements have long been recognized as a valuable indicator of neurological conditions, given the intricate involvement of multiple neurological pathways in vision-related processes, including motor and cognitive functions, manifesting in rapid response times. Eye movement abnormalities can indicate neurological condition severity and, in some cases, distinguish between disease phenotypes. With recent strides in imaging sensors and computational power, particularly in machine learning and artificial intelligence, there has been a notable surge in the development of technologies facilitating the extraction and analysis of eye movements to assess neurodegenerative diseases. This mini-review provides an overview of these advancements, emphasizing their potential in offering patient-friendly oculometric measures to aid in assessing patient conditions and progress. By summarizing recent technological innovations and their application in assessing neurodegenerative diseases over the past decades, this review also delves into current trends and future directions in this expanding field.

Keywords: computer vision; digital biomarkers; eye movement; eye tracking; machine learning; neurodegeneration; patient experience.

PubMed Disclaimer

Conflict of interest statement

All authors are employees of NeuraLight Ltd. The manuscript preparation and submission were fully funded by NeuraLight Ltd.

References

    1. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer Disease in the United States (2010–2050) estimated using the 2010 census. Neurology. (2013) 80(19):1778–83. 10.1212/WNL.0b013e31828726f5 - DOI - PMC - PubMed
    1. Dorsey ER, Elbaz A, Nichols E, Abbasi N, Abd-Allah F, Abdelalim A, et al. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. (2018) 17(11):939–53. 10.1016/S1474-4422(18)30295-3 - DOI - PMC - PubMed
    1. Gooch CL, Pracht E, Borenstein AR. The burden of neurological disease in the United States: a summary report and call to action: burden of neurological disease. Ann Neurol. (2017) 81(4):479–84. 10.1002/ana.24897 - DOI - PubMed
    1. Antoniades CA, Kennard C. Ocular motor abnormalities in neurodegenerative disorders. Eye. (2015) 29(2):200–7. 10.1038/eye.2014.276 - DOI - PMC - PubMed
    1. Przybyszewski AW, Śledzianowski A, Chudzik A, Szlufik S, Koziorowski D. Machine learning and eye movements give insights into neurodegenerative disease mechanisms. Sensors. (2023) 23(4):2145. 10.3390/s23042145 - DOI - PMC - PubMed

LinkOut - more resources